Status: Recruiting
MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
Single-arm, prospective, open-label feasibility study evaluating the technical and operational feasibility of manufacturing autologous CD19-directed CAR-T cells (MB-CART19.1) at the point of care for the treatment of relapsed or refractory B-ALL in pediatric and adult patients.
Participants needed: 12
Trial details
Age: 1+Biological sex: AllType: InterventionalSponsor: King Hussein Cancer CenterUpdated: Mar 25, 2026Locations: 1
Eligibility criteria
Age ≥ 1 year as long as if deemed fit by treating investigator [+7]
Rapidly progressive, uncontrolled disease as assessed by the treating physician... [+12]